Stock Research for ADXS


Featured Broker: Ally Invest

Get the due diligence for another stock.


ADXS Stock Chart & Research Data

The ADXS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADXS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ADXS Due diligence Resources & Stock Charts

The ADXS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADXS Detailed Price Forecast - CNN Money CNN View ADXS Detailed Summary - Google Finance
Yahoo View ADXS Detailed Summary - Yahoo! Finance Zacks View ADXS Stock Research & Analysis -

Stock Analysis

TradeIdeas View ADXS Trends & Analysis - Trade-Ideas Barrons View ADXS Major Holders - Barrons
NASDAQ View ADXS Call Transcripts - NASDAQ Seeking View ADXS Breaking News & Analysis - Seeking Alpha
Spotlight View ADXS Annual Report - OTC Report View ADXS OTC Short Report -
TradeKing View ADXS Fundamentals - TradeKing Charts View ADXS SEC Filings - Bar Chart
WSJ View Historical Prices for ADXS - The WSJ Morningstar View Performance/Total Return for ADXS - Morningstar
MarketWatch View the Analyst Estimates for ADXS - MarketWatch CNBC View the Earnings History for ADXS - CNBC
StockMarketWatch View the ADXS Earnings - StockMarketWatch MacroAxis View ADXS Buy or Sell Recommendations - MacroAxis
Bullish View the ADXS Bullish Patterns - American Bulls Short Pains View ADXS Short Pain Metrics -

Social Media Mentions

StockTwits View ADXS Stock Mentions - StockTwits PennyStocks View ADXS Stock Mentions - PennyStockTweets
Twitter View ADXS Stock Mentions - Twitter Invest Hub View ADXS Investment Forum News - Investor Hub
Yahoo View ADXS Stock Mentions - Yahoo! Message Board Seeking Alpha View ADXS Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ADXS - Insider Cow View Insider Transactions for ADXS - Insider Cow
CNBC View ADXS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADXS - OTC Markets
Yahoo View Insider Transactions for ADXS - Yahoo! Finance NASDAQ View Institutional Holdings for ADXS - NASDAQ

Stock Charts

FinViz View ADXS Stock Insight & Charts - StockCharts View ADXS Investment Charts -
BarChart View ADXS Stock Overview & Charts - BarChart Trading View View ADXS User Generated Charts - Trading View

Latest Financial News for ADXS

Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug
Posted on Wednesday May 15, 2019

Nanocap Advaxis, Inc. (NASDAQ: ADXS ) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold ...

FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
Posted on Wednesday May 15, 2019

Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer. In its letter, the FDA acknowledged that the company satisfactorily addressed all hold questions. As announced on January 23, 2019, the FDA placed a partial clinical hold on this study relating to the Agency’s requests for additional information pertaining to certain AXAL chemistry, manufacturing and controls (CMC) matters. The Agency did not cite any safety issues related to the trial and all enrolled patients continued to receive treatment, per the trial protocol.

Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference
Posted on Tuesday May 14, 2019

Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of two posters at the Frontiers in Cancer Immunotherapy conference, being held today at the New York Academy of Sciences in New York City. Both posters were first presented at the recent American Association for Cancer Research (AACR) Annual Meeting, and each has updated findings being presented today. The first presentation regarding a poster entitled “Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients (Results from KEYNOTE-046)” is conference poster #31, and will be presented by Robert Petit, Ph.D., Advaxis Chief Scientific Officer, and Mark N. Stein, M.D., FACS, Associate Professor of Medical Oncology at Columbia University Medical Center, from 4:45 to 5:30 p.m. Eastern time.

Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer
Posted on Monday May 13, 2019

Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at the end of the month. Dr. Petit will assist the Company in transitioning his duties over the next several weeks, and will continue to support the Company as an advisor and consultant in his capacity as the new Chair of the Advaxis Scientific Advisory Board, effective June 3, 2019.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.